<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2021-1S-39-44</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-1646</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ И МЕТОДИКИ</subject></subj-group></article-categories><title-group><article-title>Comparison of medical and social characteristics and quality of life of patients with primary- and secondary-progressive multiple sclerosis</article-title><trans-title-group xml:lang="ru"><trans-title>Сравнение медико-социальных характеристик и качества жизни больных с первично- и вторично-прогрессирующим рассеянным склерозом</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Власов</surname><given-names>Я. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vlasov</surname><given-names>Ya. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра неврологии и нейрохирургии</p><p>443099, Самара, ул. Чапаевская, 89</p></bio><bio xml:lang="en"><p>Department of Neurology and Neurosurgery</p><p>89, Chapaevskaya St., Samara 443099</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полярная</surname><given-names>Н. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Polyarnaya</surname><given-names>N. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>443011, Самара, ул. Фрунзе, 67/69</p></bio><bio xml:lang="en"><p>67/69, Frunze St., Samara 443011</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бойко</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Boyko</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алексей Николаевич Бойко</p><p>отдел нейроиммунологии</p><p>кафедра неврологии, нейрохирургии и медицинской генетики</p><p>117997, Москва, улица Островитянова, 1, стр. 10117997, Москва, ул. Островитянова, 1</p></bio><bio xml:lang="en"><p>Aleksey Nikolaevich Boyko</p><p>Department of Neuroimmunology</p><p>Department of Neurology, Neurosurgery, and Medical Genetics</p><p>1, Ostrovityanov St., Build 10, Moscow 1179971, Ostrovityanov St., Moscow 117997</p></bio><email xlink:type="simple">boykoan13@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Samara State Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Центр гуманитарных технологий и исследований «Социальная механика»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Center of Humanitarian Technologies and Research «Social Mechanics»</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБУ «Федеральный центр мозга и нейротехнологий» ФМБА России; ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal Center of Brain and Neurotechnologies, FMBA of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>14</day><month>09</month><year>2021</year></pub-date><volume>13</volume><issue>1S</issue><issue-title>Спецвыпуск: рассеянный склероз</issue-title><fpage>39</fpage><lpage>44</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Vlasov Y.V., Polyarnaya N.G., Boyko A.N., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Власов Я.В., Полярная Н.Г., Бойко А.Н.</copyright-holder><copyright-holder xml:lang="en">Vlasov Y.V., Polyarnaya N.G., Boyko A.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/1646">https://nnp.ima-press.net/nnp/article/view/1646</self-uri><abstract><p>Management of patients with secondary progressive multiple sclerosis (SPMS) remains one of the most challenging tasks of modern neurology. Patients with SPMS present with more severe neurological symptoms, increased hospitalization frequency, pronounced cognitive impairment in most of them, and a higher level of fatigue than patients with relapsing-remitting MS (RRMS). Another unfavorable course of MS is primary progressive MS (PPMS) when there is a steady increase in neurological disorders from the very beginning of the disease.</p><sec><title>Objective</title><p>Objective: to compare medical and social characteristics and changes in quality of life (QoL) indexes in patients with PPMS and SPMS.</p></sec><sec><title>Patients and methods</title><p>Patients and methods. In total, 437 patients with PPMS from 19 constituent entities of the Russian Federation and 500 patients with SPMS from 15 Russian Federation regions were interviewed using the original medical and social questionnaire. At the same time, we studied the QoL of patients with PPMS and SPMS using the specific MusiQoL questionnaire.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. Among the patients with PPMS, 54.3% were women and 45.7% – men. In patients with SPMS, women predominated (66.3% of women and 33.7% of men – the ratio was almost 2: 1). The degree of disability and the severity of the disease were higher in SPMS than in PPMS. The family continues to be the primary aid source in everyday life for patients with MS: 75–80% of patients who need such support receive it from their significant others. More patients with SPMS indicated a deterioration in their health status over the last year (70%, while among patients with PPMS – 55%). More patients with PPMS received outpatient care (82.1% compared to 64.7% in SPMS; p=0.01). Immobility and SPMS treatment problems were the main reasons for decreased outpatient care in patients with SPMS. Less than half of patients with SPMS (43.8%) and 62% of patients with PPMS received inpatient treatment. According to neurologists reports, there is a major problem in providing MS centers with effective drugs to treat both disease courses. When QoL was assessed, we found more profound changes in SPMS concerning both QoL's psychological and physical components. Only recently, a new drug, siponimod, has been approved for the treatment of SPMS. The lack of effective treatment formed the basis of negative attitudes towards the health care system in SPMS.</p></sec><sec><title>Conclusion</title><p>Conclusion. QoL changes reflect the patient's attitude to his condition. The introduction of new drugs for the pathogenetic treatment of SPMS (siponimod) will improve the QoL indicators in SPMS.</p></sec></abstract><trans-abstract xml:lang="ru"><p>Ведение пациентов с вторично-прогрессирующим рассеянным склерозом (ВПРС) остается одной из наиболее трудных проблем современной неврологии. При ВПРС отмечаются более тяжелые неврологические симптомы и более частые госпитализации, большинство пациентов имеют выраженные когнитивные нарушения, более высокий уровень усталости по сравнению с больными ремиттирующим РС (РРС). Другим неблагоприятным типом течения РС является первично-прогрессирующий РС (ППРС), когда имеется неуклонное нарастание неврологических нарушений с самого клинического начала заболевания.</p><p>Целью данного исследования было сравнительное изучение медико-социальных характеристик и изменений показателей качества жизни (КЖ) у больных ППРС и ВПРС.</p><sec><title>Пациенты и методы</title><p>Пациенты и методы. Всего с использованием оригинального медико-социального вопросника было опрошено 437 пациентов с ППРС из 19 субъектов Российской Федерации и 500 пациентов с ВПРС из 15 регионов Российской Федерации. Одновременно проводилось исследование КЖ пациентов с ППРС и ВПРС с использованием специфического опросника MusiQoL.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Среди пациентов с ППРС было 54,3% женщин и 45,7% мужчин, а при ВПРС женщины преобладали (66,3% женщин и 33,7% мужчин – соотношение почти 2:1). Степень инвалидизации и тяжесть состояния при ВПРС были выше, чем при ППРС. Семья продолжает оставаться основным каналом помощи в быту пациентам с РС: 75–80% пациентов, нуждающихся в такой поддержке, получают ее от своих близких. Больные с ВПРС чаще указывают на ухудшение своего самочувствия за последний год (70%, в то время как среди больных ППРС – 55%). Среди пациентов с ППРС больше тех, кто обращается в поликлинику (82,1% по сравнению с 64,7% при ВПРС; р=0,01). Основные причины снижения обращаемости больных ВПРС в поликлинику – ограничение физических возможностей передвижения, проблемы в лечении ВПРС. Стационарным лечением охвачено менее половины пациентов с ВПРС (43,8%) и 62% пациентов с ППРС. Проблема обеспечения центров РС эффективными лекарственными препаратами оценивается неврологами как довольно острая в отношении обоих типов течения заболевания. При исследовании КЖ отмечены более существенные изменения при ВПРС, касающиеся и психологической, и физической составляющих КЖ. Лишь недавно для лечения ВПРС разрешен новый препарат – сипонимод. Отсутствие эффективного лечения легло в основу негативного отношения к системе здравоохранения при ВПРС.</p></sec><sec><title>Заключение</title><p>Заключение. Изменения КЖ отражают отношение самого пациента к своему состоянию. Внедрение новых препаратов для патогенетического лечения ВПРС (сипонимода) позволит улучшить показатели КЖ и при ВПРС.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>вторично-прогрессирующий рассеянный склероз</kwd><kwd>первично-прогрессирующий рассеянный склероз</kwd><kwd>качество жизни</kwd><kwd>лечение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>secondary-progressive multiple sclerosis</kwd><kwd>primary-progressive multiple sclerosis</kwd><kwd>quality of life</kwd><kwd>treatment</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Статья спонсируется компанией «Новартис».</funding-statement><funding-statement xml:lang="en">This article has been supported Novartis.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Oh J, Alikhani K, Bruno T, et al. Diagnosis and management of secondary-progressive multiple sclerosis: time for change. Neurodegener Dis Manag. 2019 Dec;9(6):301-17. doi: 10.2217/nmt-2019-0024. Epub 2019 Nov 26.</mixed-citation><mixed-citation xml:lang="en">Oh J, Alikhani K, Bruno T, et al. Diagnosis and management of secondary-progressive multiple sclerosis: time for change. Neurodegener Dis Manag. 2019 Dec;9(6):301-17. doi: 10.2217/nmt-2019-0024. Epub 2019 Nov 26.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Popescu BF, Pirko I, Lucchinetti CF. Pathology of multiple sclerosis: where do we stand? Continuum (Minneap Minn). 2013 Aug;19(4 Multiple Sclerosis):901-21. doi: 10.1212/01.CON.0000433291.23091.65</mixed-citation><mixed-citation xml:lang="en">Popescu BF, Pirko I, Lucchinetti CF. Pathology of multiple sclerosis: where do we stand? Continuum (Minneap Minn). 2013 Aug;19(4 Multiple Sclerosis):901-21. doi: 10.1212/01.CON.0000433291.23091.65</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Tutuncu M, Tang J, Zeid NA, et al. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler. 2013 Feb;19(2):188-98. doi: 10.1177/1352458512451510. Epub 2012 Jun 26.</mixed-citation><mixed-citation xml:lang="en">Tutuncu M, Tang J, Zeid NA, et al. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler. 2013 Feb;19(2):188-98. doi: 10.1177/1352458512451510. Epub 2012 Jun 26.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Scott TF, Hackett CT, Quigley MR, Schramke CJ. Relapsing multiple sclerosis patients treated with disease modifying therapy exhibit highly variable disease progression: a predictive model. Clin Neurol Neurosurg. 2014 Dec;127:86-92. doi: 10.1016/j.clineuro.2014.09.008. Epub 2014 Oct 2.</mixed-citation><mixed-citation xml:lang="en">Scott TF, Hackett CT, Quigley MR, Schramke CJ. Relapsing multiple sclerosis patients treated with disease modifying therapy exhibit highly variable disease progression: a predictive model. Clin Neurol Neurosurg. 2014 Dec;127:86-92. doi: 10.1016/j.clineuro.2014.09.008. Epub 2014 Oct 2.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Paty DW, Boiko AN. Beta-interferons delay the switch from relapsing-remitting to secondary progressive multiple sclerosis. Neurology. 2000;54(Suppl. 3):A337.</mixed-citation><mixed-citation xml:lang="en">Paty DW, Boiko AN. Beta-interferons delay the switch from relapsing-remitting to secondary progressive multiple sclerosis. Neurology. 2000;54(Suppl. 3):A337.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Giovannetti AM, Pietrolongo E, Borreani C, et al, for the ManTra Project. Conversion to secondary progressive multiple sclerosis: Multistakeholder experiences and needs in Italy. PLoS One. 2020;15(2):e0228587. doi: 10.1371/journal.pone.0228587</mixed-citation><mixed-citation xml:lang="en">Giovannetti AM, Pietrolongo E, Borreani C, et al, for the ManTra Project. Conversion to secondary progressive multiple sclerosis: Multistakeholder experiences and needs in Italy. PLoS One. 2020;15(2):e0228587. doi: 10.1371/journal.pone.0228587</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Bogosian A, Morgan M, Moss-Morris R. Multiple challenges for people after transitioning to secondary progressive multiple sclerosis: a qualitative study. BMJ Open. 2019 Mar 8;9(3):e026421. doi: 10.1136/bmjopen-2018-026421</mixed-citation><mixed-citation xml:lang="en">Bogosian A, Morgan M, Moss-Morris R. Multiple challenges for people after transitioning to secondary progressive multiple sclerosis: a qualitative study. BMJ Open. 2019 Mar 8;9(3):e026421. doi: 10.1136/bmjopen-2018-026421</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">O'Loughlin E, Hourihan S, Chataway J, et al. The experience of transitioning from relapsing remitting to secondary progressive multiple sclerosis: views of patients and health professionals. Disabil Rehabil. 2017 Sep;39(18):1821-8. doi: 10.1080/09638288.2016.1211760. Epub 2016 Aug 16.</mixed-citation><mixed-citation xml:lang="en">O'Loughlin E, Hourihan S, Chataway J, et al. The experience of transitioning from relapsing remitting to secondary progressive multiple sclerosis: views of patients and health professionals. Disabil Rehabil. 2017 Sep;39(18):1821-8. doi: 10.1080/09638288.2016.1211760. Epub 2016 Aug 16.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kappos L, Bar-Or A, Cree BAC, et al; EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263-73. doi: 10.1016/S0140-6736(18)30475-6</mixed-citation><mixed-citation xml:lang="en">Kappos L, Bar-Or A, Cree BAC, et al; EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263-73. doi: 10.1016/S0140-6736(18)30475-6</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Scalfari A, Neuhaus A, Daumer M, et al. Onset of secondary progressive phase and longterm evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;85(1):67-75. doi: 10.1136/jnnp-2012-304333</mixed-citation><mixed-citation xml:lang="en">Scalfari A, Neuhaus A, Daumer M, et al. Onset of secondary progressive phase and longterm evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;85(1):67-75. doi: 10.1136/jnnp-2012-304333</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Katz Sand I, Krieger S, Farrell C, Miller AE. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Mult Scler. 2014;20(12):1654-7 doi: 10.1177/1352458514521517</mixed-citation><mixed-citation xml:lang="en">Katz Sand I, Krieger S, Farrell C, Miller AE. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Mult Scler. 2014;20(12):1654-7 doi: 10.1177/1352458514521517</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Gross HJ, Watson C. Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. Neuropsychiatr Dis Treat. 2017;13:1349-57. doi: 10.2147/NDT.S132079</mixed-citation><mixed-citation xml:lang="en">Gross HJ, Watson C. Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. Neuropsychiatr Dis Treat. 2017;13:1349-57. doi: 10.2147/NDT.S132079</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Бойко ОВ. Исследование качества жизни больных рассеянным склерозом. Журнал неврологии и психиатрии им. С.С.Корсакова. 2014;114(10):105-13.</mixed-citation><mixed-citation xml:lang="en">Boyko O. Studies of the quality of life of multiple sclerosis patients. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2014;114(10):105-13 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Lee Mortensen G, Rasmussen PV. The impact of quality of life on treatment preferences in multiple sclerosis patients. Patient Prefer Adherence. 2017 Oct 19;11:1789-96. doi: 10.2147/PPA.S142373. eCollection 2017.</mixed-citation><mixed-citation xml:lang="en">Lee Mortensen G, Rasmussen PV. The impact of quality of life on treatment preferences in multiple sclerosis patients. Patient Prefer Adherence. 2017 Oct 19;11:1789-96. doi: 10.2147/PPA.S142373. eCollection 2017.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ebers GC. Natural history of primary progressive multiple sclerosis. Mult Scler. 2004 Jun;10 Suppl 1:S8-13; discussion S13-5. doi: 10.1191/1352458504ms1025oa</mixed-citation><mixed-citation xml:lang="en">Ebers GC. Natural history of primary progressive multiple sclerosis. Mult Scler. 2004 Jun;10 Suppl 1:S8-13; discussion S13-5. doi: 10.1191/1352458504ms1025oa</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Попова ЕВ, Бойко АН, Барабанова МА и др. Первично-прогрессирующий рассеянный склероз: современное состояние проблемы своевременной постановки диагноза. Журнал неврологии и психиатрии им. С.С. Корсакова. 2017;117(10-2):35-40.</mixed-citation><mixed-citation xml:lang="en">Popova EV, Boyko AN, Barabanova MA, et al. Primary progressive multiple sclerosis: current issues of timely diagnosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017;117(102):35-40. doi: 10.17116/jnevro201711710235-40 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Kutzelnigg A. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005;128(11):2705-12. doi: 10.1093/brain/awh641</mixed-citation><mixed-citation xml:lang="en">Kutzelnigg A. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005;128(11):2705-12. doi: 10.1093/brain/awh641</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. Dec 2009. Available from: http://www.fdagov/downloads/drugs/guidance-complianceregulatoryinformation/guidances/ucm193282pdf</mixed-citation><mixed-citation xml:lang="en">Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. Dec 2009. Available from: http://www.fdagov/downloads/drugs/guidance-complianceregulatoryinformation/guidances/ucm193282pdf</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Apolone G, De Carli G, Brunetti M, Garattini S. Health-related quality of life (HR-QOL) and regulatory issues: an assessment of the European Agency for the Evaluation of Medicinal Products (EMEA) recommendations on the use of HR-QOL measures in drug approval. Pharmacoeconomics. 2001;19(2):187-95. doi: 10.2165/00019053-200119020-00005</mixed-citation><mixed-citation xml:lang="en">Apolone G, De Carli G, Brunetti M, Garattini S. Health-related quality of life (HR-QOL) and regulatory issues: an assessment of the European Agency for the Evaluation of Medicinal Products (EMEA) recommendations on the use of HR-QOL measures in drug approval. Pharmacoeconomics. 2001;19(2):187-95. doi: 10.2165/00019053-200119020-00005</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Tur C, Moccia M, Barkhof F, et al. Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. Nat Rev Neurol. 2018;14(2):75-93. doi: 10.1038/nrneurol.2017.171</mixed-citation><mixed-citation xml:lang="en">Tur C, Moccia M, Barkhof F, et al. Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. Nat Rev Neurol. 2018;14(2):75-93. doi: 10.1038/nrneurol.2017.171</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Fiest KM, Greenfield J, Metz LM, et al. Discriminative ability of quality of life measures in multiple sclerosis. Health Qual Life Outcomes. 2017 Dec 21;15(1):246. doi: 10.1186/s12955-017-0828-0</mixed-citation><mixed-citation xml:lang="en">Fiest KM, Greenfield J, Metz LM, et al. Discriminative ability of quality of life measures in multiple sclerosis. Health Qual Life Outcomes. 2017 Dec 21;15(1):246. doi: 10.1186/s12955-017-0828-0</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Warren S, Turpin KV, Warren KG. Healthrelated quality of life in MS: issues and interventions. Can J Neurol Sci. 2009;36(5):540-1. doi: 10.1017/S0317167100008003</mixed-citation><mixed-citation xml:lang="en">Warren S, Turpin KV, Warren KG. Healthrelated quality of life in MS: issues and interventions. Can J Neurol Sci. 2009;36(5):540-1. doi: 10.1017/S0317167100008003</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Ионова ТИ, Новик АА, Сухонос ИА. Качество жизни онкологических больных. Вопросы онкологии. 1998;44(6):749-52.</mixed-citation><mixed-citation xml:lang="en">Ionova TI, Novik AA, Zuchonos IA. Quality of life of patients with cancer. Voprosy oncologii. 1998;44(6):749-52 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Татаринова МЮ, Фокин ИВ, Бойко АН. Качество жизни больных рассеянным склерозе и некоторые подходы к фармакоэкономическим исследованиям. Журнал неврологии и психиатрии. 2002;(2-2):76-80.</mixed-citation><mixed-citation xml:lang="en">Tatarinova MYu, Fokin IV, Boyko AN. Quality of life in multiple sclerosis and pharmaco-economic studies. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2002;(2-2):76-80 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Simeoni M, Auquier P, Fernandez O, et al; MusiQol study group. Validation of the multiple sclerosis international quality of life questionnaire. Mult Scler. 2008 Mar;14(2):219-30. doi: 10.1177/1352458507080733. Epub 2007 Oct 17.</mixed-citation><mixed-citation xml:lang="en">Simeoni M, Auquier P, Fernandez O, et al; MusiQol study group. Validation of the multiple sclerosis international quality of life questionnaire. Mult Scler. 2008 Mar;14(2):219-30. doi: 10.1177/1352458507080733. Epub 2007 Oct 17.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Fernandez O, Baumstarck-Barrau K, Simeoni MC, Auquier P; MusiQoL study group. Patient characteristics and determinants of quality of life in an international population with multiple sclerosis: assessment using the MusiQoL and SF-36 questionnaires. Mult Scler. 2011;17(10):1238-49. doi: 10.1177/1352458511407951</mixed-citation><mixed-citation xml:lang="en">Fernandez O, Baumstarck-Barrau K, Simeoni MC, Auquier P; MusiQoL study group. Patient characteristics and determinants of quality of life in an international population with multiple sclerosis: assessment using the MusiQoL and SF-36 questionnaires. Mult Scler. 2011;17(10):1238-49. doi: 10.1177/1352458511407951</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Малыгин ВЛ, Бойко АН, Коновалова ОЕ и др. Влияние психопатологических факторов и особенностей личности на результаты исследования качества жизни больных рассеянным склерозом. Журнал неврологии и психиатрии им. С.С.Корсакова. 2019;119(2-2):42-8.</mixed-citation><mixed-citation xml:lang="en">Malygin VL, Boyko AN, Konovalova OE, et al. Influence of psychopathological factors and personality traits on the results of the study of quality of life in patients with multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2019;119(2-2):42-8. doi: 10.17116/jnevro20191192242 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Власов ЯВ, Полярная НВ, Фомина ТА и др. Вторично-прогрессирующий склероз в России, медико-социальная характеристика пациентов и актуальные задачи терапии. Медицинский алфавит. Неврология и психиатрия. 2021;(3):7-13. doi: 10.33667/2078-5631-2021-3-7-13</mixed-citation><mixed-citation xml:lang="en">Vlasov YaV, Polyarnaya NV, Fomina TA, et al. Secondary-progressive sclerosis in Russia, medical and social characteristics of patients and current problems of therapy. Meditsinskiy alfavit. Nevrologiya i psikhiatriya = Medical Alphabet. Neurology and Psychiatry. 2021;(3):7-13. doi: 10.33667/2078-5631-2021-3-7-13 (In Russ.).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
